Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myeloge
HM Kantarjian, S O'brien, J Cortes, FJ Giles, S Faderl, JP Issa, G Garcia-Manero, MB Rios, J Shan, M Andreeff, M Keating, M Talpaz
The estimated 3-year survival rate was less than 5% in the blastic phase and 27% in the accelerated phase.
摘自：http://www.epidna.com/showabstract.php?pmid=12879469
我更觉得Decitabine这种药物不可靠。
No comments:
Post a Comment